Patents Examined by Bao Q Li
  • Patent number: 10604559
    Abstract: This disclosure provides a multimeric hepatitis B virus (HBV) protein binding molecule, e.g., a dimeric IgA or a pentameric or hexameric IgM binding molecule, comprising at least two bivalent binding units, or variants or fragments thereof, each comprising at least two antibody heavy chain constant regions or fragments thereof, wherein each heavy chain constant region or fragment thereof is associated with an HBV antigen binding domain. The disclosure also provides compositions comprising the multimeric binding molecules, polynucleotides encoding the multimeric binding molecules, and methods to make and use the multimeric binding molecules.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: March 31, 2020
    Assignee: IGM Biosciences, Inc.
    Inventors: Stephen F. Carroll, Ramesh Baliga, Dean Ng, Bruce Keyt
  • Patent number: 10596260
    Abstract: The invention provides for modified reovirus nucleic acid sequences and modified reovirus polypeptide sequences as well as reoviruses containing such modified nucleic acid or polypeptide sequences. The invention also provides for pharmaceutical compositions that include reoviruses having a modified sequence as well as methods of making and using such reoviruses.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: March 24, 2020
    Assignee: ONCOLYTICS BIOTECH INC.
    Inventor: Matthew C. Coffey
  • Patent number: 10591480
    Abstract: Disclosed is a method for the detection of an IgM antibody specific for a flavivirus in a sample, comprising the steps of (a) contacting the sample with a solid support comprising immobilised IgM-binding molecules, (b) allowing binding of IgM antibodies in the sample to the IgM binding molecules on the solid support so that the IgM antibodies are also immobilised on the solid support, and (c) detecting IgM antibodies specific for a flavivirus by allowing binding of a complex comprising (i) an antiparallel dimer of soluble flavivirus Protein E (sE) and (ii) a marker and identifying the binding of the complex to the specific flavivirus IgM antibody by detecting the marker; and a kit suitable for performing the method.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: March 17, 2020
    Assignee: MEDIZINISCHE UNIVERSITÄT WIEN
    Inventors: Franz X. Heinz, Karin Stiasny
  • Patent number: 10588961
    Abstract: The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: March 17, 2020
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Stefano Colloca, Riccardo Cortese, Antonella Folgori, Alfredo Nicosia
  • Patent number: 10584317
    Abstract: Modified viruses and methods for preparing the modified viruses are provided. Vaccines that contain the viruses are provided. The viruses can be used in methods of treatment of diseases, such as proliferative and inflammatory disorders, including cancer, and as anti-tumor and/or antiangiogenic agents. The viruses also can be used in diagnostic methods.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: March 10, 2020
    Assignee: Genelux Corporation
    Inventors: Aladar A. Szalay, Alexa Frentzen, Yong A. Yu, Nanhai Chen, Qian Zhang
  • Patent number: 10577397
    Abstract: The present invention provides methods and compositions for protein delivery. The invention features virus like particles, methods of making virus like particles and methods of using virus like particles to deliver proteins to a cell, to provide protein therapy and to treat diseases or disorders. The invention also features methods of targeting a protein to a cell, methods of protein therapy and methods of treating diseases or disorders using a TUS protein, a NLS or NES identified from full length TUS.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: March 3, 2020
    Assignee: The USA, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Deb Chatterjee, Stanislaw Jan Kaczmarczyk
  • Patent number: 10576143
    Abstract: The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: March 3, 2020
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Stefano Colloca, Riccardo Cortese, Antonella Folgori, Alfredo Nicosia
  • Patent number: 10570191
    Abstract: This disclosure provides a multimeric human immunodeficiency virus (HIV) protein binding molecule, e.g., an dimeric IgA or a pentameric or hexameric IgM binding molecule, comprising at least two bivalent binding units, or variants or fragments thereof, each comprising at least two antibody heavy chain constant regions or fragments thereof, wherein each heavy chain constant region or fragment thereof is associated with an HIV antigen binding domain. Also provided are compositions comprising the multimeric binding molecules, polynucleotides encoding the multimeric binding molecules, and methods to make and use the multimeric binding molecules.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: February 25, 2020
    Assignee: IGM Biosciences, Inc.
    Inventors: Bruce Alan Keyt, Dan T. Stinchcomb, Ole A. Olsen
  • Patent number: 10568969
    Abstract: The present invention relates to isolated immunogenic polypeptides and their use. In one aspect, the isolated immunogenic polypeptide includes a scaffold polypeptide having a hairpin loop modified to include one or more epitopes heterologous to the scaffold polypeptide and from an amino acid loop linked by a disulfide bond. The scaffold polypeptide directs self-assembly with two other of the scaffold polypeptides to form a trimeric structure, which constrains the one or more epitopes to a conformation that is (i) substantially similar to one or more native pathogen epitopes in trimeric conformation and (ii) capable of binding an antibody reactive to the one or more native pathogen epitopes in trimeric conformation. Another aspect relates to an isolated immunogenic polypeptide that includes a scaffold polypeptide having a native loop modified to include one or more epitopes heterologous to the scaffold polypeptide and from an amino acid loop linked by a disulfide bond.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: February 25, 2020
    Assignees: New York University, Molsoft LLC, Icahn School of Medicine at Mount Sinai
    Inventors: Maxim Totrov, Xunqing Jiang, Ruimin Pan, Susan Zolla-Pazner, Xiangpeng Kong
  • Patent number: 10570377
    Abstract: The present invention relates to an oncolytic virus which is, or is derived from, a clinical isolate which has been selected by comparing the abilities of a panel of three or more clinical isolates of the same viral species to kill tumor cells of two or more tumor cell lines in vitro and selecting a clinical isolate which is capable of killing cells of two or more tumor cell lines more rapidly and/or at a lower dose in vitro than one or more of the other clinical isolates in the panel.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: February 25, 2020
    Assignee: Replimune Limited
    Inventor: Robert Coffin
  • Patent number: 10548946
    Abstract: The inventions describe here cover therapeutic compositions, and methods of use, for neutralizing Type I interferons in a mammal. The compositions contain a soluble Orthopoxvirus IFN-binding protein that is modified to remove the cell-binding region, and that specifically binds to Type I IFNs, and a pharmaceutically acceptable carrier or excipient. Another variation of the invention entails a novel IFN-binding protein that is modified to remove the cell-binding region and the signal sequence.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: February 4, 2020
    Assignee: The government of the United States, as represented by the Secretary of the Army
    Inventors: Joseph Golden, Jay Hooper
  • Patent number: 10548853
    Abstract: The present invention provides an oncolytic virus formulation and preparation method thereof. The oncolytic virus formulation comprises cell vesicles derived from apoptotic tumor cells and oncolytic viruses coated in the cell vesicles as an effective component. The oncolytic virus formulation uses cell vesicles derived from tumor cells themselves to coat the oncolytic viruses, so as to evade the body's immune system attack and can be targeted to the tumor treatment site, and improve the tumor-killing effect.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: February 4, 2020
    Assignee: HUBEI SOUNDNY BIOTECHNOLOGY CO., LTD.
    Inventor: Bo Huang
  • Patent number: 10548970
    Abstract: Attenuated G9P[6] rotavirus is disclosed herein. In some embodiments, pharmaceutical compositions are disclosed that include an attenuated G9P[6] rotavirus, or a component thereof. These compositions can be used to induce an immune response, such as a protective immune response, to a rotavirus. The compositions can be used as vaccines, such as for children (infants), for example in a prime boost strategy.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: February 4, 2020
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES
    Inventors: Baoming Jiang, Yuhuan Wang
  • Patent number: 10544206
    Abstract: The present invention provides a novel antibody capable of binding to a norovirus. The present invention is an antibody that consists of an amino acid sequence, wherein said amino acid sequence consists of, in an N- to C-direction, the following structural domains: N-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4-C wherein FR denotes a framework region amino acid sequence and CDR denotes a complementary determining region amino acid sequence; the CDR1 consists of any one of an amino acid sequences represented by SEQ ID NO: 1-SEQ ID NO: 6; the CDR2 consists of any one of an amino acid sequences represented by SEQ ID NO: 7-SEQ ID NO: 12; the CDR3 consists of any one of an amino acid sequences represented by SEQ ID NO: 13-SEQ ID NO: 17; and the antibody is capable of binding to a norovirus.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: January 28, 2020
    Assignee: PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD.
    Inventor: Keiko Yugawa
  • Patent number: 10537630
    Abstract: Described herein are improved purification methods for virus vaccines and compositions. Also described are Zika, Chikungunya, dengue and yellow fever vaccines and methods of producing and administering said vaccines to subjects in need thereof.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: January 21, 2020
    Assignee: Valneva SE
    Inventors: Jana Barbero Calzado, Mario Nebenführ, Robert Schlegl, Michael Weber, Jürgen Heindl-Wruss
  • Patent number: 10537599
    Abstract: A method for selecting cancer patient for treatment with Seneca Valley Virus (SVV) by determining expression of ANTXR1 in a cancerous tissue in a cancer patient; and designating the cancer patient as a candidate for treatment with SVV if normal levels or elevated levels of ANTXR1 expression is detected in the cancerous tissue. Also a method for treating a cancer patient with SVV is disclosed.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: January 21, 2020
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Linde Miles, John Poirier, Charles Rudin
  • Patent number: 10538744
    Abstract: This invention relates to the use of an adenovirus to treat cancer, for example. The adenovirus may be replication deficient in cells that lack Y box binding protein. The adenovirus may encode an oncogene or an oncogene product, which may transactivate at least one viral gene.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: January 21, 2020
    Inventor: Per Sonne Holm
  • Patent number: 10525127
    Abstract: The present invention Provides composition and method for stimulating immune responses against antigens without using conventional adjuvants (such as aluminum salt adjuvants, oil-in-water emulsion adjuvants, toll-like receptor agonist adjuvants, and the like). The composition contains p14.7 protein and an antigen to which the stimulated illumine responses are desired. The p14.7 protein functions as an adjuvant so that the immune responses to the antigen stimulated by the composition comprising p14.7 protein and the antigen are greater than the immune responses stimulated by the antigen alone. The current invention also provides a method for producing thermostable vaccines and a simple strategy for avoiding vaccine cold-chain maintenance by lyophilization.
    Type: Grant
    Filed: March 31, 2018
    Date of Patent: January 7, 2020
    Assignee: Femtomab
    Inventor: Wenyun Zhou
  • Patent number: 10517942
    Abstract: Creation of HIV-1 vaccine immunogens based on glycopeptide scaffolds containing sequences from the V1/V2/V3 and C3 domains of HIV-1 gp120 that is able to bind multiple broadly neutralizing antibodies when expressed in mammalian cells that incorporate mannose-5 and mannose-9 glycans.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: December 31, 2019
    Assignee: The Regents of the University of California
    Inventors: Phillip Berman, Rachel Doran, Gabriel Byrne, Rebecca Dubois, Javier Morales, Bin Yu, Gerardo Perez, Kathryn Mesa, David Alexander
  • Patent number: 10519220
    Abstract: The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: December 31, 2019
    Assignee: Massachusetts Institute of Technology
    Inventors: Ram Sasisekharan, Kannan Tharakaraman